7f2m › Citations

Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.

Huang YY, Deng J, Tian YJ, Liang J, Xie X, Huang Y, Zhu J, Zhu Z, Zhou Q, He X, Luo HB
J Med Chem 64 13736-13751 (2021)
Related entries: 7f2k, 7f2l

Cited: 4 times
EuropePMC logo PMID: 34520193

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, and its incidence rate is rapidly rising. However, effective therapies for the treatment of IPF are still lacking. Phosphodiesterase 4 (PDE4) inhibitors were reported to be potential anti-fibrotic agents, but their clinical use was hampered by side effects like emesis and nausea. Herein, structure-based hit-to-lead optimizations of natural mangostanin resulted in the novel and orally active PDE4 inhibitor

Reviews citing this publication (2)

  1. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Kolb M, Crestani B, Maher TM. Eur Respir Rev 32 220206 (2023)
  2. Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis. Yang X, Xu Z, Hu S, Shen J. Front Pharmacol 14 1111393 (2023)

Articles citing this publication (2)



Quick links